$9.54
2.47% today
Nasdaq, Oct 03, 03:48 pm CET
ISIN
US4884451075
Symbol
ZVRA

KemPharm, Inc. Target price 2025 - Analyst rating & recommendation

KemPharm, Inc. Classifications & Recommendation:

Buy
93%
Hold
7%

KemPharm, Inc. Price Target

Target Price $25.50
Price $9.31
Potential
Number of Estimates 9
9 Analysts have issued a price target KemPharm, Inc. 2026 . The average KemPharm, Inc. target price is $25.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 13 Analysts recommend KemPharm, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the KemPharm, Inc. stock has an average upside potential 2026 of . Most analysts recommend the KemPharm, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 23.61 103.05
14.02% 336.47%
EBITDA Margin -341.42% -72.45%
92.91% 78.78%
Net Margin -446.89% 65.56%
166.48% 114.67%

10 Analysts have issued a sales forecast KemPharm, Inc. 2025 . The average KemPharm, Inc. sales estimate is

$103m
Unlock
. This is
66.16% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$110m 77.09%
Unlock
, the lowest is
$94.1m 51.69%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $23.6m 14.02%
2025
$103m 336.47%
Unlock
2026
$159m 54.26%
Unlock
2027
$256m 61.25%
Unlock
2028
$344m 34.10%
Unlock
2029
$403m 17.25%
Unlock
2030
$475m 17.80%
Unlock
2031
$501m 5.64%
Unlock
2032
$512m 2.08%
Unlock

3 Analysts have issued an KemPharm, Inc. EBITDA forecast 2025. The average KemPharm, Inc. EBITDA estimate is

$-74.7m
Unlock
. This is
38.65% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-76.9m 42.73%
Unlock
, the lowest is
$-71.7m 33.21%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-80.6m 65.86%
2025
$-74.7m 7.38%
Unlock
2026
$35.6m 147.68%
Unlock
2027
$94.9m 166.48%
Unlock
2028
$159m 67.42%
Unlock
2029
$205m 29.36%
Unlock

EBITDA Margin

2024 -341.42% 92.91%
2025
-72.45% 78.78%
Unlock
2026
22.39% 130.90%
Unlock
2027
37.01% 65.30%
Unlock
2028
46.20% 24.83%
Unlock
2029
50.97% 10.32%
Unlock

10 KemPharm, Inc. Analysts have issued a net profit forecast 2025. The average KemPharm, Inc. net profit estimate is

$67.6m
Unlock
. This is
2,459.09% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$71.7m 2,616.29%
Unlock
, the lowest is
$61.5m 2,231.06%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-106m 129.12%
2025
$67.6m 164.03%
Unlock
2026
$30.8m 54.37%
Unlock
2027
$105m 239.99%
Unlock
2028
$177m 68.83%
Unlock
2029
$217m 22.38%
Unlock
2030
$225m 4.09%
Unlock
2031
$238m 5.73%
Unlock
2032
$267m 11.96%
Unlock

Net Margin

2024 -446.89% 166.48%
2025
65.56% 114.67%
Unlock
2026
19.39% 70.42%
Unlock
2027
40.89% 110.88%
Unlock
2028
51.49% 25.92%
Unlock
2029
53.74% 4.37%
Unlock
2030
47.49% 11.63%
Unlock
2031
47.53% 0.08%
Unlock
2032
52.13% 9.68%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.28 1.23
75.38% 153.95%
P/E 7.59

10 Analysts have issued a KemPharm, Inc. forecast for earnings per share. The average KemPharm, Inc. EPS is

$1.23
Unlock
. This is
2,975.00% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.30 3,150.00%
Unlock
, the lowest is
$1.12 2,700.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.28 75.38%
2025
$1.23 153.95%
Unlock
2026
$0.56 54.47%
Unlock
2027
$1.90 239.29%
Unlock
2028
$3.21 68.95%
Unlock
2029
$3.93 22.43%
Unlock
2030
$4.09 4.07%
Unlock
2031
$4.33 5.87%
Unlock
2032
$4.85 12.01%
Unlock

P/E ratio

Current 232.75 5,346.96%
2025
7.59 96.74%
Unlock
2026
16.63 119.10%
Unlock
2027
4.89 70.60%
Unlock
2028
2.90 40.70%
Unlock
2029
2.37 18.28%
Unlock
2030
2.27 4.22%
Unlock
2031
2.15 5.29%
Unlock
2032
1.92 10.70%
Unlock

Current KemPharm, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JMP Securities
Locked
Locked
Locked Aug 13 2025
Cantor Fitzgerald
Locked
Locked
Locked Jul 10 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 02 2025
Cantor Fitzgerald
Locked
Locked
Locked May 14 2025
Guggenheim
Locked
Locked
Locked Mar 13 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 13 2025
Canaccord Genuity
Locked
Locked
Locked Mar 13 2025
Analyst Rating Date
Locked
JMP Securities:
Locked
Locked
Aug 13 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Jul 10 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 02 2025
Locked
Cantor Fitzgerald:
Locked
Locked
May 14 2025
Locked
Guggenheim:
Locked
Locked
Mar 13 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 13 2025
Locked
Canaccord Genuity:
Locked
Locked
Mar 13 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today